ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed:
1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL
https://library.ehaweb.org/eha/2024/e...

2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):
https://library.ehaweb.org/eha/2024/e...

3. 3-year follow-up of TRANSFORM (Liso-Cel vs CITASCT in R/R DLBCL): https://meetings.asco.org/abstracts-p...

4. ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/e...

5. HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/la...

6. Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/e...

7. Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/e...